Stay updated on CTL019 in Adult ALL: Efficacy & Safety Clinical Trial
Sign up to get notified when there's something new on the CTL019 in Adult ALL: Efficacy & Safety Clinical Trial page.

Latest updates to the CTL019 in Adult ALL: Efficacy & Safety Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a Phase 2 study of CTL019 in adults with relapsed or refractory B-cell ALL, including its study details and eligibility criteria. The record indicates that the study was withdrawn and did not enroll participants.SummaryDifference35%

- Check19 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0, while the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide notice announces the NIH transition from “Artificial Intelligence” to “Super Intelligence” terminology. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the detailed trial information with a generic error page. A minimal header/footer is displayed and a revision notice is shown indicating the page content is no longer accessible at this URL.SummaryDifference16%

Stay in the know with updates to CTL019 in Adult ALL: Efficacy & Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTL019 in Adult ALL: Efficacy & Safety Clinical Trial page.